Compare HCA Health Inc (HCA) vs Infosys Limited (INFY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HCA Health Inc vs Infosys Limited — how do they compare? HCA Health Inc trades at $443.69 (market cap $95.08B), while Infosys Limited trades at $10.74 (market cap $41.69B). The key difference: HCA Health Inc is far larger — about 2.3× Infosys Limited's market cap, and Infosys Limited pays the higher dividend (4.96%). Which is the better fit depends on your goals — on Pluang, investors hold HCA Health Inc for 76 Days and Infosys Limited for 27 Days on average.
| HCA | INFY | |
|---|---|---|
Market Cap | $95.08B | $41.69B |
Volume | 998,787 | 28,397,442 |
Sector | Health | Technology |
52-Week High | $545.13 | $20.22 |
52-Week Low | $361.32 | $10.49 |
Typical Hold Time | 76 Days | 27 Days |
Enterprise Value | $145.62B | $39.44B |
Dividend Yield | 0.71% | 4.96% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HCA Healthcare (HCA) trades at $445.01, up 2.96% today, with a bullish technical signal and strong earnings beats in recent quarters. Revenue grew to $75.6B in 2025, with net income of $6.78B, and the stock trades at a P/E of 14.73. Analyst consensus is a Buy with a $461.12 price target, though ongoing legal investigations pose a headwind.
The outlook remains positive given solid demand and cost controls, but risks include payer-mix pressure and high debt levels. Upside potential exists if earnings growth continues, but investors should monitor legal developments and interest rate impacts on the leveraged balance sheet.
INFY trades at $10.55, showing no change recently. The stock is in a bearish technical trend, with moving averages signaling sell pressure, while oscillators are neutral. Fundamentally, the company reported $19.28B in revenue for 2025 with a net income margin of 16.37%, and valuation ratios like a P/E of 13.02 suggest relative affordability. Recent news highlights strategic AI collaborations, such as with Columbia University and ABN Amro, aiming to drive innovation. Earnings history is mixed, with a beat in Q1 2026 but a miss in Q2 2026.
The outlook for INFY is cautious, with analyst consensus at a $11.48 price target and a 'Hold' bias (55% of ratings). Opportunities include strong profitability metrics like a 32.12% ROE and AI-driven growth initiatives, but risks involve bearish technical signals, potential earnings volatility, and competitive pressures in IT services. Net cash flow turned negative in 2026, indicating financial strain, which could limit upside near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About HCA Health Inc
HCA Healthcare is a Nashville-based healthcare provider organization operating the largest collection of acute-care hospitals in the U.S. As of December 2021, the firm owned and operated 182 hospitals, 125 freestanding outpatient surgery centers, and a broad network of physician offices, urgent care clinics, and freestanding emergency rooms across nearly 20 states and a small foothold in England.
Read more on HCA →About Infosys Limited
Infosys is a global leader in next-generation digital services and consulting. It enables clients in more than 50 countries to navigate their digital transformation through AI-powered cloud and data solutions.
Read more on INFY →
